Última actualización 5 de julio de 2026
Key finding
Circulating omentin-1 levels were lower in DM2 versus controls.
This study examined omentin-1 levels in patients with Type 2 Diabetes and their relationship to cardiac dysfunction, finding decreased levels linked to diastolic function.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Extended (5–20+ y)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study examined omentin-1 levels in patients with Type 2 Diabetes and their relationship to cardiac dysfunction, finding decreased levels linked to diastolic function.
Understanding the relationship between omentin-1 levels and cardiac function in Type 2 Diabetes could help in developing targeted therapies. Since cardiac dysfunction is a common complication in diabetes, identifying effective treatments like pioglitazone may improve patient outcomes and reduce cardiovascular risks.
The study design was non-randomized, which may introduce bias. Sample size and demographic characteristics were not specified. Findings may not be generalizable to all populations with diabetes.
Published in
Publication details and source links for this paper.
Sabrina G, Weena JYC, Bujar M, et al. Omentin-1 Levels Are Decreased in Patients with Type 2 Diabetes and Linked to Cardiac Dysfunction. PLoS ONE. 2013;8(3):e59697. doi:10.1371/journal.pone.0059697
Circulating omentin-1 levels were lower in DM2 patients compared to controls (P < 0.05).
Pioglitazone treatment improved diastolic function and increased omentin-1 levels by 1.5 ng/mL (P = 0.001).
No significant difference in omentin-1 levels was observed between metformin and control groups (P = 0.45).
No significant difference in diastolic function parameters was found between metformin and control groups (P = 0.5).
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Metformin, Pioglitazone and Diastolic function parameters, Omentin-1.
This study contributes evidence to
Primary intervention
Metformin
Primary outcomes
Evidence topics
Primary intervention
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
2
Related topics
4
Evidence pairs
33
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Tema de evidencia
matched_intervention
Evidencia relacionada
Tema de evidencia
Guardar evidencia
Core evidence
The primary outcomes reported in this study.
Metformin → Diastolic function parameters
Metformin → Diastolic function parameters
Pioglitazone → Diastolic function parameters
Pioglitazone → Diastolic function parameters
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Metformin Therapies and Diastolic function parameters, Metformin Therapies and Omentin-1.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring Diastolic function parameters
Measures Diastolic function parameters as a key outcome.
All studies on Metformin Therapies
Contributes to Metformin Therapies evidence base.
All studies measuring Omentin-1
Measures Omentin-1 as a key outcome.
Jump to pre-filtered views in Evidence Explorer.
1 results
1 results
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
Pioglitazone appears to improve Diastolic function parameters.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Diastolic function parameters
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Pioglitazone appears to improve Omentin-1.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Omentin-1
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of Metformin for Diastolic function parameters.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Diastolic function parameters
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of Metformin for Omentin-1.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Omentin-1
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Centrada en la evidencia, no en la publicidad.
Tus datos siempre están protegidos.
Se agregan nuevos estudios todos los días.
